Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Eortc QLQ-OES18 Yaşam Kalitesi Modülünün Türkçe Çevirisi ve Validasyonu

Abstract

We intended to translate the `European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Oesophagus 18? (EORTC QLQ-OES18) module into Turkish, and validate it. We also aimed to evaluate the quality of life in head and neck cancer patients by using this module together with the `Quality of Life Questionnaire-Core 30? (QLQ-C30), and `Head and Neck 35? (H&N35) modules, and the effect of arginine in oral mucositis, and esophagitis in the subgroup who used arginine containing solution (Abound®). We identified 31 head and neck patients who received Intensity Modulated Radiation Therapy (IMRT) in Hacettepe University Faculty of Medicine, Department of Radiation Oncology between December 27th, 2012, and July 19th, 2013, and whose oral feeding was normal prior to treatment. 90% of the patients received concurrent, and 45% received induction CT, where 29% of them had surgery prior to radiotherapy (RT). 17 of the patients used Abound® twice daily. In the first part of this study, we translated QLQ-OES18 module into Turkish, and validated it with the approval of EORTC. In the second part, we applied this module together with the QLQ-C30 and H&N35 modules to the patients on the first, 15th, and the last days of RT. The patients were also evaluated for oral mucositis and esophagitis weekly during RT in terms of Radiation Therapy Oncology Group Cooperative Group Common Toxicity Criteria (RTOG CGCTT) Stomatitis, Common Terminology Criteria for Adverse Events (CTCAE) Oral Mucositis, Oral Pain, and Dysphagia. In EORTC QLQ-C30, H&N35, and OES18 modules the global health, functional scales, and the symptoms were found to be deteriorated in all patients. Worsening in scores of RTOG and CTCAE criteria were also seen in proceeding RT weeks. When we compared patients who used Abound® to who did not, no statistical difference was found in global health status, but emotional and social functions, and symptoms of pain, loss of appetite, dry mouth, feeling ill, opening mouth, sticky saliva, social eating problems, sense problems, swallowing, social contact problems, dysphagia, eating, reflux, swallowing saliva, and taste problems were found to be worse in the subgroup of not using- Abound®. Patients using Abound® had less, and slighter symptoms than the ones who did not in the proceeding weeks of RT in terms of RTOG and CTCAE scores. This study has proved the applicability of EORTC QLQ-OES18 module in Turkish population of head and neck cancer patients who receives IMRT. We have also shown the quality of life is deteriorated with RT, but can be less deteriorated by using arginine-containing solutions.